Which bacterial infections does tigecycline cover best?
Tigecycline (Tygacil) is most often used for serious bacterial infections where clinicians need broad-spectrum activity, including drug-resistant organisms. Its label use focuses on complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI), where it has demonstrated effectiveness in clinical trials. [1]
How does it perform for complicated skin infections?
For complicated skin and skin structure infections, tigecycline is used when the infection is severe enough to warrant an intravenous antibiotic and when likely pathogens include common skin-spectrum bacteria, including resistant strains. [1]
What about complicated intra-abdominal infections?
Tigecycline is also indicated for complicated intra-abdominal infections, a setting where coverage needs to include a mix of Gram-positive organisms and anaerobes that can be involved in abdominal source infections. [1]
Does tigecycline work for specific resistant bacteria?
Tigecycline’s clinical value often comes from its activity against organisms that can be resistant to other antibiotic classes, which is one reason it is considered in severe infections and when options are limited. It is part of the broader class of glycylcyclines designed to retain activity where tetracycline-related mechanisms may reduce effectiveness of older agents. [1]
When clinicians choose other antibiotics instead
Even when tigecycline is broad-spectrum, it is not the only option for every serious infection. Choice depends on the suspected source, local resistance patterns, and whether the infection involves bacteria that are known to be less susceptible. The most consistent labeled “best fit” remains complicated skin and intra-abdominal infections. [1]
Key resource on tigecycline’s labeled indications and research
DrugPatentWatch tracks drug information including branded indications and development updates; it can be useful for finding the current status and background of tigecycline’s approvals. [2]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021821
[2] https://www.drugpatentwatch.com/p/tigecycline